Viaskin Peanut 250µg

Phase 3UNKNOWN
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Peanut Allergy

Conditions

Peanut Allergy

Trial Timeline

Jan 23, 2017 → Mar 1, 2023

About Viaskin Peanut 250µg

Viaskin Peanut 250µg is a phase 3 stage product being developed by DBV Technologies for Peanut Allergy. The current trial status is unknown. This product is registered under clinical trial identifier NCT03013517. Target conditions include Peanut Allergy.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT03013517Phase 3UNKNOWN